Open AccessAppropriate use of antifungal agents
Author(s) -
Elio Castagnola
Publication year - 2013
Publication title -
reviews in health care
Language(s) - English
Resource type - Journals
eISSN - 2038-6702
pISSN - 2038-6699
DOI - 10.7175/rhc.v4i1s.861
Subject(s) - medicine , authorization , intensive care medicine , order (exchange) , product (mathematics) , drug , liability , family medicine , pharmacology , law , computer security , business , computer science , geometry , mathematics , finance , political science
As knowledge increases faster and faster, authorizations for drug use often don’t report the most recent evidence. In addition, trials on pediatric populations are rare: as a consequence, a lot of drugs in pediatrics are prescribed out of their indications. This is called off-label use, if the drug isn’t approved for the treatment of a specific disease, or unauthorized use, if, for example, a dose isn’t written in the summary of product characteristics. These uses aren’t illegal, but physicians should take some steps in order to protect their liability: for example, the hospital should write documents based on shared scientific evidence, where the reasons supporting a choice are explained. Informed consent should be obtained, after an exhaustive explanation, from the parents. There is also the exceptional use, i.e. the use in desperate cases, where no other treatments are possible, but, for example, a study in an animal model has resulted in good outcomes. Even in this case, similar measures should be taken by the physician.